Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues

Journal of Medicinal Chemistry

Volumn 52, Issue 21, 2009, Pages 6599-6605

  Marquis, Robert W ^a   Lago, Amparo M ^a   Callahan, James F ^a   Rahman, Attiq ^a   Dong, Xiaoyang ^a   Stroup, George B ^a   Hoffman, Sandra ^a   Gowen, Maxine ^a   DelMar, Eric G ^b   Van Wagenen, Bradford C ^b   Logan, Sarah ^b   Shimizu, Scott ^b   Fox, John ^b   Nemeth, Edward F ^b   Roethke, Theresa ^a   Smith, Brian R ^a   Ward, Keith W ^a   Bhatnagar, Pradip ^a  

^a GLAXOSMITHKLINE   (United States)

^b NPS Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[3 [[1,1 DIMETHYL 2 (2 NAPHTHALENYL)ETHYL]AMINO] 2 HYDROXYPROPYL]OXY]BENZONITRILE; 2 CYANOPHENOL; 2 OXIRANYLMETHANOL; 3 [3 CYANO 4 [[3 [[1,1 DIMETHYL 2 (2 NAPHTHALENYL)ETHYL]AMINO] 2 HYDROXYPROPYL]OXY]PHENYL]PROPANOIC ACID; 3 [4 [[3 [[1,1 DIMETHYL 2 (2 NAPHTHALENYL)ETHYL]AMINO] 2 HYDROXYPROPYL]OXY]PHENYL]PROPANOIC ACID; 4 HYDROXYHYDROCINNAMATE; [1,1 DIMETHYL 2 (2 NAPHTHALENYL)ETHYL]AMINE; AMINOALCOHOL; AMPHOLYTE; CALCIUM RECEPTOR 2 ANTAGONIST; CARBOXYLIC ACID; EPOXIDE; ESTER; ETHYL 3 [3 CYANO 4 [[3 [[1,1 DIMETHYL 2 (2 NAPHTHALENYL)ETHYL]AMINO] 2 HYDROXYPROPYL]OXY]PHENYL]ROPANOATE; ETHYL 4 HYDROXYHYDROCINNAMATE; FURETHIDINE; HORMONE ANTAGONIST; PARATHYROID HORMONE; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; BONE DENSITY; BROMINATION; CONTROLLED STUDY; CYANATION; DISTRIBUTION VOLUME; DRUG ACTIVITY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROLYSIS; PERMEABILITY;

ADMINISTRATION, ORAL; AMINO ALCOHOLS; ANIMALS; BIOLOGICAL AVAILABILITY; CALCIUM; CELL LINE; CYTOPLASM; DOGS; ESTERS; HUMANS; PARATHYROID HORMONE; PERMEABILITY; PHENYLPROPIONATES; PRODRUGS; PROPANOLAMINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, CALCIUM-SENSING; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 71049164708     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900563e     Document Type: Article

References (45)

1. Bonnick, S. L. Osteoporosis in men and women. Clin. Cornerstone 2006, 8, 28-39.
2. Bodenner, D.; Redman, C.; Riggs, A. Teriparatide in the management of osteoporosis. Clin. Interventions Aging 2007, 2, 499-507.
3. Bilezikian, J. P. Anabolic therepy for osteoporosis. Women's Health 2007, 3, 243-253.
4. Girotra, M.; Rubin, M. R.; Bilezikian, J. P. The use of parathyroid hormone in the treatment of osteoporosis. Rev. Endocr. Metab. Disord. 2006, 7, 113-121.
5. Eriksen, E. F.; Robins, D. A. Teriparatide: a bone formation treatment for osteoporosis. Drugs Today 2004, 40, 935-948.
6. Quattrocchi, E.; Kourlas, H. Teriparaitide: a review. Clin. Ther. 2004, 26, 841-854.
7. Dobnig, H. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis. Expert Opin. Pharmacother. 2003, 57, 710-718.
8. Ebling, P. R.; Russell, R. G. G. Teriparaitide (rhPTH1-34) for the treatment of osteoporosis. Int. J. Clin. Pract. 2003, 57, 710-718.
9. Berg, C.; Neumeyer, K.; Kirkpatrick, P. Fresh from the pipline: teriparatide. Nat. Rev. Drug Discovery 2003, 2, 257-258.
10. Brown, E. M.; MacLeod, R. J. Extracellular calcium sensing and extracellular calcium signaling. Physiol. Rev. 2001, 81, 239-297.
11. Nemeth, E. F. Calcium receptor-dependent regulation of cellular functions. News Physiol. Sci. 1995, 10, 1-5.
12. Brown, E. M.; MacLeod, R. J. Extracellular calcium sensing and extracellular calcium signaling. Physiol. Rev. 2001, 81, 239-297.
13. Chen, R. A.; Goodman, W. G. Role of the calcium-sensing receptor in parathyroid gland physiology. Am. J. Physiol.: Renal Physiol. 2004, 286, F1005-F1011.
14. Tfelt-Hansen, J.; Brown, E. M. The calcium-sensing receptor in normal physiology and pathophysiology: a review. Crit. Rev. Clin. Lab. Sci. 2005, 42, 35-70.
15. Locatelli, F.; Pontoriero, G.; Limbardo, M.; Tentori, F. Cinacalcet hydrochloride: calcimimnetic for the treatment of hyperparathyroidism. Expert Opin. Endocr. Metabol. 2006, 1, 167-179.
16. Dong, B. J. Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism. Clin. Ther. 2005, 27, 1725-1751.
17. de Francisco, A. L. M.; Cinacalcet, H. C. L. A novel therapeutic for the treatment of hyperparathyroidism. Expert Opin. Pharmacother. 2005, 6, 441-452.
18. +2 receptor antagonists that stimulate secretion of parathyroid hormone. J. Pharmacol. Exp. Ther. 2001, 299, 323-331.
19. Gowen, M.; Stroup, G. B.; Dodds, R. A.; James, I. E.; Votta, B. J.; Smith, B. R.; Bhatnagar, P. K.; Lago, A. M.; Callahan, J. F.; Del Mar, E. G.; Miller, M. A.; Nemeth, E. F.; Fox, J. Antagonizing the parathyroid calcium receptor stimulates parathyroid secretion and bone formation in osteopenic rats. J. Clin. Invest. 2000, 105, 1595-1604.
20. Arey, B. J.; Seethala, R.; Ma, Z.; Fura, A.; Morin, J.; Swartz, J.; Vyas, V.; Yang, W.; Dickson, J. K., Jr.; Feyen, J. H. M. A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo. Endocrinology 2005, 5, 1131-1136.
21. 2-(1-aryl)ethyl-3-phenylpropane-1,2- diamines as novel calcimimetics acting on the calcium sensing receptor. Bioorg. Med. Chem. Lett. 2000, 10, 2001-2004.
22. 1-(1-(1-naphthyl)ethyl)-3-phenylpropane-1,2- diamines and conformationally constrained indole analogues: development of calindol as a new calcimimetic acting at the calcium-sensing receptor. Bioorg. Med. Chem. Lett. 2004, 14, 3345-3349.
23. 2-(1-(1-naphthyl)ethyl)- 1,2-diaminocyclohexanes: a new class of calcilytic agents acting at the calcium-sensing receptor. ChemBioChem 2004, 5, 1131-1136.
24. Arey, B. J.; Seethala, R.; Ma, Z.; Fura, A.; Morin, J.; Swartz, J.; Vyas, V.; Yang, W.; Dickson, J. K., Jr.; Feyen, J. H. M. A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo. Endocrinology 2005, 5, 1131-1136.
25. Yang, W.; Wang, Y.; Roberge, J. Y.; Ma, Z.; Liu, Y.; Lawerence, R. M.; Rotella, D. P.; Seethala, R.; Feyen, J. H. M.; Dickson, J. K., Jr. Discovery and structure activity relationships of benzylpyrrolidine substituted aryloxypropanols as calcium-sensing receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 1225-1228.
26. Gavai, A. V.; Vaz, R. J.; Mikkilineni, A. B.; Roberge, J. Y.; Liu, Y.; Lawrence, R. M.; Corte, J. R.; Yang, W.; Bednarz, M.; Dickson, J. K., Jr.; Ma, Z.; Seethala, R.; Feyen, J. H. M. Discovery of novel 1-arylmethyl pyrrolidin-2-yl ethanol amines as calcium-sensing receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 5478-5482.
27. Shcherbakova, I.; Balandrin, M. F.; Fox, J.; Ghatak, A.; Heaton, W.; Conklin, R. L. 3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis. Bioorg. Med. Chem. Lett. 2005, 15, 1557-1560.
28. Shcherbakova, I.; Huang, G.; Geoffroy, O. J.; Nair, S. K.; Swierczek, K.; Balandrin, M. F.; Fox, J.; Heaton, W. L.; Conklin, R. L. Bioorg. Med. Chem. Lett. 2005, 15, 2537-2540.
29. Dobnig, H.; Turner, R. T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995, 136, 3632-3638.
30. Ishizuya, T.; Yokose, S.; Hori, M.; Noda, T.; Suda, T.; Yoshiki, S.; Yamaguchi, A. Parathyroid hormone exerts disparate effects on osteoclast differentiation depending on exposure time in rat osteoblastic cells. J. Clin. Invest. 1997, 99, 2961-2970.
31. Frolik, C. A.; Black, E. C.; Cain, R. L.; Satterwhite, J. H.; Brown-Augsburger, P. L.; Sato, M.; Hock, J. M. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 2003, 33, 372-379.
32. Onyia, J. E.; Helvering, L. M.; Gelbert, L.; Wei, T.; Huang, S.; Chen, P.; Dow, E. R.; Maran, A.; Zhang, M.; Lotinun, S.; Halladay, D. L.; Miles, R. R.; Kulkarni, N. H.; Ambrose, E. M.; Ma, Y. L.; Frolik, C. A.; Sato, M.; Bryant, H. U.; Turner, R. T. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis of DNA microarray. J. Cell. Biochem. 2005, 95, 403-418.
33. Marquis, R. W.; Lago, A. M.; Callahan, J. F.; Trout, R. E. L.; Gowen, M.; DelMar, R. G.; Van Vegnan, B. C.; Logan, S.; Shimizu, S.; Fox, J.; Nemeth, E. F.; Yang, Z.; Roethke, T.; Smith, B. R.; Ward, K. W.; Lee, J.; Keenan, R. M.; Bhatnagar, P. Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues. J. Med. Chem. 2009, 52, 3982-3993.
34. Crivori, P.; Poggesi, I. Predictive model for identifying potential CYP2D6 Inhibitors. Basic Clin. Pharm. Toxicol. 2005, 96, 251-253.
35. Ekins, S.; Gianpaolo, B.; Binkley, S.; Gillespie, J. S.; Ring, B. J.; Winkel, J. H.; Wrighton, S. A. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics 1999, 9, 477-489. (Pubitemid 29419566)
36. De Groot, M. J.; Ackland, M. J.; Horne, V. A.; Alex, A. A.; Jones, B. C. Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. J. Med. Chem. 1999, 42, 1515-1524.
37. Rowland, P.; Blaney, F. E.; Smyth, M. G.; Jones, J. J.; Leydon, V. R.; Oxbrow, A. K.; Lewis, C. J.; Tennant, M. G.; Modi, S.; Eggleston, D. S.; Chenery, R. J.; Bridges, A. M. Crystal structure of the human cytochrome P450 2D6. J. Biol. Chem. 2006, 281, 7614-7622.
38. Mitcheson, J. S. hERG potassium channels and the structural basis of drug-induced arrhythmias. Chem. Res. Toxicol. 2008, 21, 1005-1010.
39. Kramer, C.; Beck, B.; Kriegel, J. M.; Clark, T. A composite model for hERG blockade. ChemMedChem 2008, 3, 254-265.
40. Stansfeld, P. J.; Gedeck, P.; Gosling, M.; Cox, B.; Mitcheson, J. S.; Sutcliffe, M. J. Drug block of the hERG potassium channel: insights from modeling. Proteins: Struct., Funct., Bioinf. 2007, 68, 568-580.
41. Sanguinetti, M. C.; Tristani-Firouzi, M. hERG potassium channels and cardiac arrhythmia. Nature 2006, 440, 463-469.
42. Sanguinetti, M. C.; Mitcheson, J. S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol. Sci. 2005, 26, 119-124.
43. Fernandez, D.; Ghanta, A.; Kauffman, G. W.; Sanguinetti, M. C. Physiochemical features of the hERG channel binding site. J. Biol. Chem. 2004, 279, 10120-10127.
44. Tonioli, C.; Crisma, M.; Formaggio, F.; Peggion, C. Control of peptide conformation by the Thorpe-Ingold effect (C-α tetrasubstitution). Biopolymers 2001, 60, 396-419. (Pubitemid 35000909)
45. See first two references of ref 6.